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Introduction
The majority of human tumors maintain indefi  nite replicative 
potential through the activation of telomerase. Although telo-
m  erase activity is the more common mechanism used to maintain 
telomeres, a number of tumors, tumor-derived, and in vitro–
immortalized cell lines have been shown to maintain telomeres 
in the absence of telomerase. These cells use a recombination-
based mechanism that has been termed alternative lengthening 
of telomeres (ALT) (Bryan et al., 1995). In particular, ALT tumors 
mainly include specifi  c subtypes of soft tissue sarcomas associated 
with complex karyotypes, astrocytic brain tumors and osteo-
sarcomas (Muntoni and Reddel, 2005).
The onset of ALT is determined by the appearance of het-
erogenous telomere length, high rates of telomeric sister chromatid 
exchange (T-SCE) (Londono-Vallejo et al., 2004), the presence 
of extra-chromosomal telomeric DNA, and the appearance of 
ALT–associated promyelocytic leukemia bodies (APBs) (Yeager 
et al., 1999). This nuclear body is distinct from the promyelocytic 
leukemia body (PML-NB), which is a subnuclear structure pre-
sent in most cell types and tissues (Salomoni and Pandolfi  , 2002). 
PML is a tumor suppressor inactivated in acute promyelocytic 
leukemia (APL) and the essential component of the PML-NB 
(Salomoni and Pandolfi  , 2002). In addition to PML, the APB 
contains telomeric DNA, DNA repair proteins such as MRE11, 
NBS1 and Rad50, RPA, Rad52, and the telomere repeat binding 
factors TRF1 and TRF2 (Yeager et al., 1999; Wu et al., 2000, 
2003; Zhu et al., 2000; Naka et al., 2002).
TRF2 is a sequence-specifi  c DNA binding protein that 
binds the duplex array of  TTAGGG repeats at human telomeres. 
It has been shown to protect telomeres from end-to-end fusions 
through the formation of the t-loop (de Lange, 2002). The over-
expression of TRF2 causes telomere attrition in vitro and in vivo 
(Karlseder et al., 2002; Blanco et al., 2007). Evidence has recently 
emerged suggesting a role for TRF2 as an oncogene in the 
absence of telomerase. Overexpression of TRF2 in the skin of 
telomerase-defi  cient mice accelerates carcinogenesis and increases 
telomere recombination, implying that TRF2 is oncogenic and 
favors the activation of ALT (Blanco et al., 2007). In this respect, 
TRF2 was found overexpressed in hepatocellular carcinoma (Oh 
et al., 2005). Furthermore, TRF2 has been shown to delay the 
onset of senescence by protecting critically short telomeres from 
fusion and repressing chromosome end-to-end fusions in pre-
senescent cultures (Karlseder et al., 2002). Uncapped telomeres 
resemble double-strand breaks and it is the presence of the telo-
mere capping complex, named shelterin (de Lange, 2005), that 
circumvents the activation of a DNA damage response. Removal 
of TRF2 results in the localization of active ATM to the unpro-
tected telomeres (Takai et al., 2003), eventually inducing ATM-
dependent apoptosis in telomerase-positive tumor cell lines or 
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stantial loss of telomeric DNA upon stable TRF2 knockdown 
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irreversible cell cycle arrest in primary cells (Karlseder et al., 
1999, 2002). TRF2 has been shown to interact with ATM, through 
S1981 in an unphosphorylated state, and block its activation 
(Karlseder et al., 2004). Interestingly, ATM is involved in telo-
mere maintenance in fl  ies, which lack telomerase and maintain 
their telomeres through transposition, thus suggesting that also 
in vertebrates ATM’s role may not be limited to inducing a DNA 
damage response (Bi et al., 2005). Remarkably, recent studies 
demonstrate that indeed ATM is important in regulating the telo-
mere end structure after replication and ATM inhibition results 
in telomere end-to-end fusions (Verdun et al., 2005; Verdun and 
Karlseder, 2006). Nevertheless, it is currently unclear whether 
ATM has a role in ALT.
The tumor suppressor p53 is a downstream target of ATM 
and is required for the induction of apoptosis and senescence 
upon TRF2 down-regulation. It has been proposed that p53 spe-
cifi  cally inhibits DNA synthesis and delays exit from S phase in 
ALT cells by interfering with telomeric recombination (Razak 
et al., 2004). PML is a known modulator of p53 and regulates its 
function at multiple levels: (i) it induces p53 accumulation into 
PML-NBs upon stress, thus causing p53 acetylation and tran-
scriptional activation (Pearson et al., 2000); and (ii) it sequesters 
Mdm2 to the nucleolus, thus indirectly inhibiting p53 ubiquity-
lation and degradation (Bernardi et al., 2004). Vice versa, PML 
itself is a transcriptional target of p53, thus adding a degree of 
complexity to the whole picture (de Stanchina et al., 2004). 
Despite several studies indicating that p53 can associate with 
PML in the PML-NB, it is still an object of controversy whether 
p53 localization to PML-NB is required for its activation.
In this study, we set out to determine the effects of alterations 
to the shelterin complex on ALT cells. To this end, we decided 
to interfere with the function of the shelterin component TRF2 by 
multiple approaches. Interestingly, lack of TRF2 leads to loss of 
telomeric DNA and genomic instability. However, this is not 
associated with a marked induction of cell death, but rather with 
decreased growth and induction of cellular senescence. Further-
more, in ALT cells, unlike in telomerase-positive cells, ATM is 
constitutively active, but it is only upon TRF2 down-regulation 
or inhibition that the ATM target p53 is phosphorylated and acti-
vated. In this context, PML is essential for p53-dependent in-
duction of p21. Overall, our fi  ndings provide new insights into the 
consequences of shelterin alterations in ALT cells.
Results
Effects of TRF2 knockdown in ALT cells
We fi rst set out to determine the effect of TRF2 down-regulation 
on colony formation of ALT cells. To stably silence TRF2, we 
constructed expression vectors encoding shRNAs for TRF2 and 
introduced them in U2OS cells, which are p53-profi  cient. TRF2 
knockdown reproducibly resulted in decreased number of colo-
nies in colony-forming assays (Fig. 1 A). A number of clones 
derived from isolated colonies displayed a substantial decrease 
in TRF2 protein levels both by Western blotting and immuno-
fl  uorescence (Fig. 1 B and Fig. 3 A). As inhibition of TRF2 
in telomerase-positive cells lines leads to induction of apop-
tosis, we analyzed apoptosis levels in TRF2-depleted clones. 
Only a modest increase in apoptosis was observed in the G10 
TRF2 shRNA clone by both subdiploid peak analysis and 
Hoechst staining (Fig. 1, C and D). We next used a dominant-
negative TRF2 mutant, ∆B∆M, which lacks both the Basic 
and Myb domain and sequesters endogenous TRF2 away from 
telomere ends (van Steensel et al., 1998). We generated U2OS 
clones stably expressing ∆B∆M (Fig. S1 A, available at http://
www.jcb.org/cgi.content/full/jcb.200703020/DC1) and analyzed 
levels of spontaneous apoptosis by Hoechst staining. A marginal 
increase in apoptotic cells was detected only in one of the two 
∆B∆M clones (G3), thus suggesting that ALT cells can escape 
some of the consequences of TRF2 inactivation (Fig. 1 E). To con-
fi  rm the growth-suppressive effect of TRF2 silencing in a more 
controlled system, we generated inducible clones expressing 
shRNAs against TRF2 under the control of doxycycline (DOX). 
Western blotting and immunofl  uorescence analyses demonstrated 
that expression of TRF2 was completely shut down 72 h after the 
addition of DOX (Fig. 1 F). Importantly, formation of colonies was 
clearly decreased in the presence of DOX, thus confi  rming data 
obtained using the stable TRF2 knockdown (Fig. 1, A and G).
As lack of substantial cell death induction in TRF2-
  depleted cells could be the result of selection of resistant clones 
through compensatory mechanisms acting on the apoptosis 
  machinery, we set to determine the immediate effects of TRF2 
 depletion/inactivation in transient expression experiments. TRF2 
was knocked down using RNAi oligonucleotides in U2OS cells 
(Fig. S1 B). Strikingly, transient TRF2 silencing had no effect 
whatsoever on cell death up to 72 h (Fig. S1 C). Furthermore, 
apoptosis was not induced upon DOX treatment in inducible 
clones up to 72 h (unpublished data). Finally, transient expres-
sion of ∆B∆M (Fig. S1 D, left) did not lead to induction of cell 
death compared with empty vector-transfected cells (Fig. S1 D, 
right). Similar results were obtained using the p53-defi  cient ALT 
cell line SAOS2 (Fig. S3 D, available at http://www.jcb.org/
cgi.content/full/jcb.200703020/DC1; and unpublished data). 
In contrast, ∆B∆M induced cell death in HeLa in transient, and 
we were unable to obtain stable clones (unpublished data).
In telomerase-positive cells, lack of TRF2 at telomeres in-
duces end-to-end fusions, which is the result of the de-inhibition 
of the nonhomologous end joining mechanism (NHEJ). To test 
whether end-to-end fusions could be induced in ALT cells, we 
stained metaphases from ∆B∆M-transfected U2OS cells with a 
telomeric PNA probe to visualize telomeres. Cytogenetic analysis 
of U2OS metaphases from sorted cells transiently expressing the 
∆B∆M allele showed  16% (13/81 cells) contained long chains 
of fused chromosomes with multiple internal telomere signals 
and ring chromosomes (Fig. S1 E). This indicates that tran-
sient expression of the ∆B∆M allele causes chromosome fusion 
via NHEJ in a minority of U2OS ALT+ cells in contrast to the 
high frequency of fusions seen in telomerase + cells (van Steensel 
et al., 1998). The decreased proportion of metaphases displaying 
end-to-end fusions may explain why ALT cells appear to cope 
better following TRF2 down-regulation or inactivation. For in-
stance, following clonal selection and expansion none of the G10 
TRF2-depleted or control cells (pRS26) contained long chains 
of telomere-telomere fused chromosomes (0/25 cells for each 
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Despite the substantial lack of end-to-end fusions, TRF2-
depleted U2OS cells displayed features of genomic instability. 
First, several mitotic fi  gures in TRF2-depleted cells were abnormal 
(51/119 in G10 cells versus 20/218 in control cells), as several 
anaphase bridges and lagging chromosomes were clearly detected 
(Fig. S2 A, available at http://www.jcb.org/cgi.content/full/jcb
.200703020/DC1). This was accompanied by increased nuclear 
size and/or aberrant morphology detected in more than 60% of 
TRF2-depleted cells. In addition to this, we found a proportion 
of polynucleated cells in cultures of TRF2-depleted cells (11%), 
and a small number (1–2%) of tripolar mitoses were also pre-
sent (Fig. S2, A and B). Aberrant nuclear morphology was also 
detected in ∆B∆M-expressing cells in transient, in ∆B∆M-
expressing clones and in mixed populations (Fig. S2 C). We also 
detected numerous micronuclei in TRF2-depleted cells, which 
can be the result of either lagging chromosomes or supernumerary 
centrosomes (G10 clone; Fig. S2 B) (Brinkley, 2001; Kirsch-
Volders et al., 2002). Indeed, supernumerary centrosomes were 
found in TRF2-depleted cells, thus suggesting the presence of 
centrosomal dysfunction (unpublished data).
Interestingly, TRF2-depleted cells appeared larger than con-
trol cells (Fig. S2 D). This prompted us to run TRF2-defi  cient 
cells through a CASY counter and a cytometer. A clear increase 
in cell size was demonstrated in independent TRF2-defi  cient 
Figure 1.  Effects of PML and TRF2 stable down-
regulation. (A) TRF2 knockdown suppresses colony 
formation. U2OS cells were transfected with empty 
pRETROsuper (Ctrl) or with pRS shRNA expression 
vectors targeting TRF2 (shTRF2) and selected for 
10 d. Cells were stained using crystal violet, and 
colonies were counted. Representative pictures 
are shown. Graph represents means of three ex-
periments  ± standard deviations. (B) Colonies 
from pRS and TRF2-pRS-transfected cells were 
picked and analyzed by SDS-PAGE using anti-
TRF2 and anti-Actin antibodies. Control clones are 
indicated. (C) Modest induction of apoptosis in 
stable TRF2-depleted clones. F8 and G10 cells 
were stained with propidium iodide and analyzed 
using a cytometer. Subdiploid peaks are indicated. 
Histograms are representative of three indepen-
dent experiments, while values represent means of 
experiments ± standard errors. (D) Hoechst stain-
ing of live cells shows increased apoptotic nuclei 
in G10 cells. Histograms are representative of 
three independent experiments, while values rep-
resent means of experiments ± standard errors. 
(E) Hoechst staining of live cells shows increased 
apoptotic nuclei in ∆B∆M-expressing clones. Histo-
grams are representative of three independent 
experiments, while values represent means of 
  experiments ± standard errors. (F) TetON inducible 
U2OS clones F1 and F11 lose TRF2 expression 
following doxycycline (DOX) induction (three days). 
SDS-PAGE was blotted with anti-TRF2 and anti-Actin 
antibodies (top). Induced and un-induced cells were 
also stained for immunoﬂ  uorescence using anti-TRF2 
antibodies (bottom). (G) Colony formation is im-
paired in inducible cells cultured in the presence of 
doxycycline. The same number of cells from F1 and 
F11 clones were plated and cultured in the presence 
of DOX for two weeks. Number of colonies is shown. 
Representative of two independent experiments with 
similar results.JCB • VOLUME 179 • NUMBER 5 • 2007  858
clones compared with control ones (Fig. S2 E). Furthermore, DOX-
dependent down-regulation of TRF2 in inducible clones also re-
sulted in increased cell size at all time points analyzed (Fig. S2 F).
As induction of cell death is very likely not a major contribu-
tor of the observed decrease in colony formation, diminished pro-
liferation is the most plausible explanation. To test this, we analyzed 
cell cycle profi  les in TRF2-depleted cells and found an increase in 
the proportion of cells in the G2 phase of cell cycle (Fig. 2 A). 
Mixed populations of sorted cells expressing the ∆B∆M mutant 
also displayed an accumulation in the G2 phase (Fig. 2 B), and 
similar changes were observed in ∆B∆M-expressing clones 
(Fig. 2 C). Finally, we studied proliferation in inducible clones 
and found that the number of TRF2-depleted cells compared 
with control uninduced cells progressively decreases following 
addition of DOX (Fig. 2 D). Increased cell size and diminished 
proliferation are two of the features of cellular senescence. 
  Indeed, upon DOX treatment inducible clones became strongly 
positive for acidic βgal (SA-βgal), a marker of cellular senes-
cence (Fig. 2 E).
APB status in TRF2-depleted cells
As TRF2 is one of the constituents of APBs, we set to investi-
gate whether TRF2 depletion/inactivation has an effect on APB 
formation. Stable TRF2 down-regulation did not affect PML 
  localization and the colocalization between TRF1 and MRE11, 
which constitutes a marker for APBs (Fig. 3 A and unpublished 
data). Importantly, colocalization between PML, TRF1 and telo-
meric DNA was also not affected (Fig. 3 B). Nevertheless, a 
  decrease in the overall number of APBs was observed, which 
however correlates with a reduction in the intensity of telomeric 
foci in each nucleus (Fig. 3, C and D). To determine whether the 
observed effects on telomeric signals could be applied also to 
other ALT cells, we generated TRF2-depleted clones of the 
ALT cell line SUSM1 (Fig. S3 A, top set of panels). Indeed, the 
intensity of telomeric signal was reduced also in TRF2-depleted 
SUSM1 clones (Fig. S3 A, bottom set of panels). In contrast, 
TRF2 transient down-regulation in U2OS cells did not have an 
effect on the overall number of APBs, as measured by presence 
of MRE11/TRF1 and MRE11/PML foci (Fig. S3, B and C; and 
unpublished data). Finally, another ALT cell line, SAOS2, was 
used to confi  rm the effect of TRF2 depletion on APBs. Also in 
this case, MRE11 localization was not affected by transient 
TRF2 silencing (Fig. S3 D). Next, we extended our analysis to 
∆B∆M-expressing cells in both transient and stable settings. 
Transient expression of Myc-tagged ∆B∆M (Fig. 3 E) had no 
effect on the colocalization between telomeric DNA (PNA 
staining) and PML and the percentage of cells displaying co-
localization (Fig. 3 E and unpublished data). We next studied 
PML/PNA colocalization in stable ∆B∆M clones. As seen in 
TRF2-depleted U2OS cells, in stable ∆B∆M clones the inten-
sity of PNA foci appeared to be decreased compared with cells 
transfected with an empty vector (Fig. 3 F). By performing 3D 
reconstruction of confocal images, we also found that the num-
ber of telomeric foci was diminished (Fig. 3 F). APBs were pre-
sent in ∆B∆M clones, albeit at a reduced number (Fig. 3 F and 
unpublished data). It is worth noting that the overall proportion 
of foci containing both PML and telomeric DNA in each given 
cell did not change, thus suggesting that the reduction in the 
number of APBs is probably caused by a decrease in the number 
of foci containing telomeric DNA (unpublished data).
TRF2 down-regulation affects telomere 
length in ALT cells
One of the possible explanations for the decreased intensity 
and smaller number of PNA foci in cells lacking TRF2 is that 
Figure 2.  Cell cycle alterations and cellular senescence in cells lacking 
TRF2. (A) TRF2-depleted U2OS clones display increased accumulation in 
the G2 phase of cell cycle. Fixed control and TRF2 depleted clones were 
stained with propidium iodide (PI) and analyzed for cell cycle proﬁ  les. 
Data shown are means of three independent experiments ± SEM. (B) ∆B∆M-
expressing mix populations show increased accumulation in the G2 phase. 
U2OS cells were transfected with GFP and control or ∆B∆M vectors and 
sorted. Cells were analyzed for cell cycle distribution using PI. Data shown 
are means of three independent experiments ± SEM. (C) ∆B∆M-expressing 
clones accumulate in the G2 phase. ∆B∆M-expressing clones were ana-
lyzed for cell cycle proﬁ  les using PI staining. Data shown are means 
of three independent experiments ± SEM. (D) Inducible TRF2 depletion 
results in decreased proliferation. Inducible shRNA clones were treated 
with doxycycline or left untreated, and cells were counted at different pas-
sages from stimulation. Data are representative of two independent experi-
ments with similar results and are expressed as percentage of un-induced 
control. (E) Induction of cellular senescence upon TRF2 knockdown. Induc-
ible clones F1 (left two panels) and F11 (right two panels) were cultured in 
the absence or presence of Doxycycline for 7 d and stained for SA-βGal. 
Images were acquired by light microscopy.THE ROLE OF TRF2 IN ALT CELLS • STAGNO D’ALCONTRES ET AL. 859
telomeres are affected. To test this, we analyzed telomere length 
by pulse-fi  eld gel analysis of digested genomic DNA followed 
by Southern blot hybridization using a telomere-specifi  c probe. 
We conducted our analysis on empty vector-transfected clones 
(pRS25, pRS26), shTRF2-expressing clones that did not show 
TRF2 down-regulation (C5, F8) and on TRF2-depleted clones 
(G10, C3, D2, C8). Surprisingly, TRF2-depleted U2OS clones dis-
played shorter telomeres and decreased telomeric signal (Fig. 4 A). 
Quantitative analysis of the telomere length using the Telometric 
software confi  rmed that telomeres are indeed shorter in cells 
lacking TRF2 (Fig. 4 A, bottom). We extended our analysis to a 
different passage for clones F8, G10, C3 and C8 (additional popu-
lation doublings: F8+5.22pd; C3+4.34pd; D2+4.46; G10+4.2) 
and obtained similar results (unpublished data). This may indicate 
that the number of population doublings between two time points 
was insuffi  cient to detect progressive shortening of telomeres. 
Figure 3.  Effect of TRF2 knockdown or inactivation on 
APBs.  (A) PML speckled distribution is not affected by 
TRF2 inactivation in U2OS clones. F8 (Ctrl) and G10 (sh-
TRF2) clones were stained with anti-TRF2 and anti-PML anti-
bodies and counterstained with DAPI. (B) TRF1 and PML 
accumulate at telomeric foci (PNA) in TRF2-depleted cells. 
Cells were stained with anti-PML and anti-TRF1 antibodies 
and postﬁ  xed. Then, coverslips were dehydrated and pro-
cessed for FISH. (C) Telomeric signal is decreased in TRF2-
depleted cells and number of PML/PNA/PML foci is also 
reduced. Cells were processed as in B. (D) Percentage of 
MRE11/TRF1 foci is also decreased in TRF2-depleted 
cells. Insets show F8 and G10 cells stained with anti-TRF1 
(green) and anti-MRE11 antibodies (red; merge signals). 
DAPI was used to label nuclei. Arrows indicate TRF1/
MRE11 positive speckles. Data shown are means of three 
independent experiments ± SEM. (E) Transient expression 
of the ∆B∆M TRF2 mutant does not affect PML/PNA co-
localization in transient. U2OS cells were transfected with 
an expression vector encoding Myc-tagged ∆B∆M TRF2 
(∆B∆M) or a control vector (Ctrl) and stained with anti-
Myc-tag and PML antibodies. Cells were then post-ﬁ  xed 
and processed for FISH. DAPI was used to stain nuclei. 
(F) Number of telomeric foci is reduced in ∆B∆M-expressing 
stable clones. Control vector and ∆B∆M TRF2 clones were 
hybridized with a PNA telomeric probe and analyzed by 
confocal microscopy. Then, images were 3D-reconstructed. 
Approximately 100 cells each ﬁ  eld were analyzed. Data 
shown are means of three independent experiments ± 
SEM. (G) APBs are present in ∆B∆M-expressing clones. 
Control (Ctrl) and ∆B∆M clones were stained with anti-PML 
antibodies, post-ﬁ  xed and processed for FISH as in B.JCB • VOLUME 179 • NUMBER 5 • 2007  860
In this respect, the fact that TRF2-depleted clones tend to lose 
silencing through time did not allow us to calculate the short-
ening rate. Moreover, we found that stable TRF2 depletion in 
a different ALT cell line, SUSM1, led to telomere shortening, 
albeit to a lesser extent, and to a markedly decreased total hy-
bridization signal, thus demonstrating that the loss of telomeric 
DNA is not limited to a single ALT cell line (Control clone B9, 
TRF2-depleted clones C3, C7 and C11; Fig. 4 B). The de-
creased intensity of the signal in TRF2-depleted cells is not due 
to uneven loading, as demonstrated by using a probe for the 
minisatellite MS1 (Fig. S4, A and B; available at http://www
.jcb.org/cgi.content/full/jcb.200703020/DC1). Loss of telo-
meric DNA was confi  rmed in U2OS and SUSM1 clones using 
FlowFISH (Fig. S4 C). To our knowledge, this is fi  rst report 
describing an effect of TRF2 knockdown on telomeric DNA 
in ALT cells.
ATM status in ALT cells
Inactivation of TRF2 in telomerase-positive tumor cells or pri-
mary fi  broblasts causes the uncapping of telomeres, which are 
then recognized as DNA damage sites. This in turn results in ATM 
activation and induction of p53-dependent cell death or cellular 
senescence depending on the cell type and transformation status 
(Bartkova et al., 2006; Di Micco et al., 2006; Mallette et al., 
2007). We reasoned that TRF2 down-regulation in ALT cells 
could have a similar effect. To this end, we analyzed ATM acti-
vation by using an antibody recognizing phosphorylated serine 
1981, which is an accepted activation marker. Surprisingly, we 
observed that phosphorylated ATM (P-ATM) is present in 100% 
of control and TRF2-depleted cells and accumulates in nuclear 
speckles (Fig. 5 A). Approximately 10 ATM speckles were found 
in each nucleus of parental or empty vector-transfected U2OS 
(Fig. 5 C and unpublished data). To demonstrate that the staining 
was specifi  c, we treated U2OS cells with caffeine, which is an 
inhibitor of ATM and ATR. The P-ATM signal was indeed almost 
completely abolished in cells cultured with 10 mM caffeine for 
45 min (unpublished data). We next analyzed whether P-ATM 
colocalized with PML and telomeric foci. Remarkably,  25% 
of cells displayed ATM/PML colocalization and in each cell 
half of P-ATM speckles coincided with PML (Fig. 5, B and C; 
52 ± 8.65% and unpublished data). P-ATM also colocalized 
with PNA (and PML) in U2OS cells (Fig. 5, B and C), and 
nearly 40% of P-ATM foci contained PNA in U2OS and SAOS2 
cells (Fig. 5, B, C, and E and unpublished data). In addition, 
colocalization between P-ATM, PNA and TRF2 was demon-
strated in both U2OS and SAOS2 cells (Fig. 5, E and F). Finally, 
PNA/PML colocalization was also detected in SUSM1 cells 
(Fig. S5 A, available at http://www.jcb.org/cgi.content/full/
jcb.200703020/DC1). However, a percentage of P-ATM speck-
les were negative for either PML or TRF2, thus suggesting that 
P-ATM can also localize to nuclear domains or sites of DNA 
damage other than APBs in ALT cells. To determine whether ATM 
Figure 4.  Shortening of telomeres in TRF2-
  depleted ALT cells. (A) TRF2-depleted U2OS clones 
display shorter telomeres and decreased telo-
meric DNA hybridization. DNA from empty vec-
tor (pRS25, pRS26), TRF2-depleted clones (G10, 
C3, D2, C8) and clones expressing TRF2 shRNA 
but not displaying down-regulation (C5, F8) 
were digested and size separated by PFGE. The 
resulting Southern blots were hybridized to a 
telomere speciﬁ  c probe and telomere length was 
measured using the Telometric software (bottom 
table). (B) In TRF2-depleted SUSM-1 clones (C3, 
C7, C11) compared with a empty vector clone 
(B9) telomere length is also reduced and there is 
a substantial reduction in telomeric DNA signal. 
Two different passages are shown (additional 2.5 
population doublings). DNAs were processed 
as in A. Bottom table shows Telometric analysis of 
telomere length. THE ROLE OF TRF2 IN ALT CELLS • STAGNO D’ALCONTRES ET AL. 861
targets were phosphorylated in ALT cells, we stained U2OS with 
an antibody directed against phosphorylated ATM/ATR targets 
and found that all P-ATM speckles are also positive for phos-
phorylated ATM/ATR targets (Fig. S5 B). We next analyzed 
the phosphorylation status and localization patterns of the ATM 
target NBS1 using phospho-specifi  c antibodies. NBS1 was indeed 
phosphorylated in ALT cells and colocalized with PML and 
P-ATM in  23% of cells (Fig. S5 B; unpublished data). In con-
trast, nuclei of telomerase-positive HeLa and MCF7 did not 
display ATM/ATR targets-positive speckles (Fig. S5 C; unpub-
lished data). Finally, primary BJ fi  broblasts were also negative for 
P-ATM (Fig. S5 D). In summary, P-ATM is found in ALT cells at 
steady state, in part accumulates in APBs, and a number of its 
targets are phosphorylated and partially colocalize with APBs.
Effect TRF2 down-regulation or functional 
inhibition on p53 activation
As p53 is phosphorylated at serine 15 upon ATM activation, we 
analyzed p53 phosphorylation status at this residue in ALT cells. 
We analyzed a panel of ALT and telomerase-positive cell lines 
and found that p53 was phosphorylated (P-p53) in three differ-
ent ALT cell lines, VA13, GM847 and JFCF6 (Fig. S5 E). How-
ever, similar amounts of P-p53 were also found in the related 
cell line JFCF6-T, which is telomerase-positive (Fig. S5 E). 
Figure 5.  ATM is phosphorylated and localizes at APBs in ALT cells. (A) ATM is phosphorylated at serine 1981 in control U2OS cells and TRF2-depleted 
cells. F8 and G10 clones were stained using an anti-S1981 ATM antibody (P-ATM). Nuclei were stained using DAPI. Figures shown are representative of 
three independent experiments. (B) P-ATM accumulates at PML-positive telomeric foci (APBs) in U2OS cells. Cells were stained with anti-PML antibody and 
post-ﬁ  xed. Cells were then dehydrated and process for FISH using a FITC-conjugated PNA probe. DAPI was used to visualize nuclei. (C) Most ATM/PNA 
speckles are positive for PML. Graph shows number of P-ATM, P-ATM/PNA, P-ATM/PNA/PML speckles each nucleus. (D) P-ATM colocalizes with PML 
and telomeric foci also in SAOS2 cells. Cells were processed as in (B). (E) (F) PNA/P-ATM speckles are also positive for TRF2 in U2OS (E) and SAOS2 (F). 
Cells were stained with anti-P-ATM, anti-TRF2 antibodies and then post-ﬁ  xed. Coverslips were processed for FISH using a FITC-labeled PNA probe. DAPI was 
used to visualize nuclei.JCB • VOLUME 179 • NUMBER 5 • 2007  862
VA13, JFCF6 and JFCF6-T have been immortalized using SV40 
T antigen, thus suggesting that the presence of high p53 levels is 
due to the immortalization process or the presence of T antigen 
per se. In contrast, p53 was not phosphorylated in the remaining 
telomerase-positive and ALT cell lines (Fig. S5 E). We focused 
on U2OS cells, which are the only available p53-profi  cient ALT 
cell lines not expressing SV40 T antigens. As mentioned above, 
p53 is not phosphorylated in control U2OS cells (F8; Fig. 6 A). 
However, in TRF2-depleted cells (G10) p53 is phosphorylated 
and its levels increased (Fig. 6 A). This was accompanied by the 
induction of the p53 target gene and cell cycle inhibitor p21 
(Fig. 6 A). p21 expression is dependent on p53 in osteosarcoma 
cells, while in p53-defi  cient SAOS2 cells p21 is expressed at 
very low levels and does not respond to genotoxic stress (unpub-
lished data). In contrast, p53 proapoptotic targets, such Bax and 
Puma were not affected (unpublished data). We then analyzed 
p53 status in U2OS clones expressing ∆B∆M and found that 
p53 was induced at protein levels and was phosphorylated at 
serine 15 (Fig. 6 B). Furthermore, p21 was augmented in ∆B∆M 
cells (Fig. 6 B). To exclude an effect due to clonal selection, we 
transfected U2OS cells with either a ∆B∆M expressing vector 
or control vector in conjunction with GFP. Cells were sorted, se-
lected and analyzed after two weeks for p53 activation. Indeed, 
p53 was phosphorylated and p21 increased in ∆B∆M express-
ing cells, while p53 levels were not affected (Fig. 6 C).
As apoptosis is not induced in cells ∆B∆M-transfected 
U2OS cells in transient, we studied whether p53 was activated 
in these settings. U2OS were cotransfected with ∆B∆M or con-
trol plasmid and GFP, and sorted. In sorted ∆B∆M-expressing 
cells p53 phosphorylation was not induced and p21 levels were 
unchanged (Fig. 6 D). To substantiate these fi  ndings in a more 
controlled system, we followed p53 phosphorylation in shRNA 
inducible clones. Similar to what was seen in transient transfec-
tion experiments, p53 phosphorylation was not increased early 
on after induction despite the complete down-regulation of 
TRF2 (three days; Fig. 6 E, left). In contrast, P-p53 levels were 
augmented at 10 d, and p21 was also induced (Fig. 6 E, right; 
unpublished data), thus suggesting that in ALT cells p53 activa-
tion is not an immediate consequence of TRF2 down-regulation 
or inactivation.
We next analyzed the localization of p53 in U2OS cells, 
and found that more than 20% of cells displayed p53 in nuclear 
speckles, which were also positive for PML, TRF1, TRF2 and 
telomeric DNA (Fig. 7 A and Fig. S5 F). In contrast, p53 localiza-
tion to APBs was diminished upon TRF2 silencing (Fig. S5 G). 
Also in ∆B∆M clones p53 accumulation in APBs was decreased 
following TRF2 depletion (Fig. S5 H). This is very likely due to 
the reduced number of APBs and of foci containing telomeric 
DNA we have observed in stable clones lacking TRF2. p53 failed 
to colocalize with TRF1, TRF2 and PML in telomerase-positive 
MCF-7 and HeLa (unpublished data). Interestingly, in SUSM-1 
p53 is mutated and still accumulates at APBs (unpublished data) 
(Mihara et al., 1996), thus indicating that p53 mutation status 
does not infl  uence its localization to APBs. Because TRF2 ap-
pears to colocalize with p53, we tested whether it interacts with 
p53 by coimmunoprecipitation. While p53 was readily detected 
in anti-PML immunoprecipitates (IP), TRF2 was not found in 
anti-p53 IP, and, vice versa, p53 was not detected in anti-TRF2 
IPs (Fig. S5 I). This suggests that TRF2, at least in these experi-
mental conditions, does not interact with p53 directly.
Figure 6.  p53 is activated upon prolonged 
TRF2 down-regulation or inactivation. (A) p53 
is phosphorylated and p21 induced in a TRF2-
depleted clone. Control (F8) and TRF2-depleted 
(G10) clones were stained with anti-p53, anti-
phosphor serine 15 p53 (P-p53), anti-p21 and 
anti-Actin antibodies. Data are representative of 
two independent experiments with similar results. 
(B) p53 is activated in ∆B∆M-expressing U2OS 
clones. Extracts from empty vector (A5, B3) 
and ∆B∆M-expressing (G3, D6) clones were 
probed as in (A). Data are representative of 
two independent experiments with similar re-
sults. (C) p53 is activated also in mix popula-
tions from control vector- and ∆B∆M-transfected 
U2OS cells. Extracts were analyzed as in (A) 
and (B). (D) Transient inactivation of TRF2 does 
not lead to p53 activation. U2OS cells were 
transfected with control or ∆B∆M vectors, and 
with GFP. Cells were then sorted, cultured for 
10 d and then selected for additional ﬁ   ve 
days. p53 activation was studied as in (B), (C). 
(E) Effects of short-term (left) or long-term (right) 
TRF2 down-regulation using a doxycycline 
(DOX)-inducible system. Inset in left panel shows 
p53 phosphorylation in shTRF2 stable clone. 
Two independent inducible clones (F1, F11) 
were treated with DOX for 3 (left) or 10 d (right) 
and analyzed for p53 activation as in (D).THE ROLE OF TRF2 IN ALT CELLS • STAGNO D’ALCONTRES ET AL. 863
PML is essential for p53 activation upon 
TRF2 knockdown
PML has been previously shown to regulate p53 localization to 
PML-NB in primary or telomerase-positive cells (Salomoni and 
Pandolfi  , 2002). However, its role in regulating p53 localization 
in ALT cells was unknown. To test this, we knocked down PML 
transiently and analyzed p53 localization. Surprisingly, PML de-
pletion did not affect p53 colocalization with TRF2 and P-ATM, 
thus indicating that PML does not regulate p53 localization to 
dysfunctional/recombining telomeres (Fig. 7 A and unpublished 
data). Steady-state levels of the p53 target gene p21 were not 
affected by PML down-regulation either (unpublished data), again 
suggesting that the role of PML lies elsewhere. Then, we set out to 
determine whether PML regulates p53 function in TRF2-depleted 
cells. To this end, we transfected scrambled and PML RNAi oligo-
nucleotides into TRF2-depleted G10 cells and analyzed the effect 
of PML down-regulation on p53 activation. Remarkably, the 
induction of p21 was completely abolished in PML-depleted G10 
cells, thus indicating that PML is indispensable for p53 activa-
tion upon TRF2 silencing (Fig. 7 B). In contrast, no effect on p53 
phosphorylation or total protein levels was detected, thus sug-
gesting that PML does not interfere with ATM-dependent p53 
phosphorylation or p53 stability in this context (Fig. 7 B).
Discussion
The involvement of TRF2 and the shelterin complex in telomere 
protection and maintenance has been extensively studied in 
telomerase-positive tumor cell lines. However, the role of TRF2 
in ALT cells has not been investigated in depth. For this reason, 
we used a number of approaches, ranging from RNAi to functional 
inhibition, to manipulate TRF2 function in ALT cells. Colony 
formation experiments clearly show that RNAi-mediated TRF2 
knockdown results in a marked decrease in the number of col-
onies, thus implicating an effect on either apoptosis or cell cycle, 
or both. Nevertheless, we fi  nd that apoptosis is not induced in 
TRF2-depleted cells or in cells expressing the dominant-negative 
∆B∆M mutant in transient, and only moderately in stable set-
tings. In a previous study, the ALT cell line SAOS2 was shown 
to be resistant to the cytotoxic effects of TRF2 inactivation, and 
this was ascribed to the absence of p53 (Karlseder et al., 1999). 
However, we show here that U2OS cells, which, unlike SAOS2, 
possess an intact p53 pathway, are resistant to the apoptotic 
effect of TRF2 knockdown, indicating that the presence of p53 
is not suffi  cient to cause cell death. Remarkably, p53 is not 
activated in U2OS cells following transient TRF2 silencing or 
∆B∆M-induced inactivation. This is not due to lack of telomere 
Figure 7.  p53 activation upon TRF2 silencing 
relies on PML. (A) PML does not affect p53 lo-
calization to TRF2-containing speckles. U2OS 
cells were electroporated with RNAi oligos 
against nuclear PML isoforms (PML) or control 
scrambled oligos (SO) and stained with anti-
TRF2, anti-p53 and anti-PML antibodies. (B) PML 
silencing abrogates p21 induction in TRF2-
depleted U2OS cells. The TRF2-depleted G10 
clone was electroporated with PML RNAi oli-
gos and analyzed for expression of PML, p21, 
Bax, P-p53, p53 and Actin using relevant anti-
bodies. Data representative of two independent 
experiments with similar results. (C) Proposed 
model for TRF2 function in ALT cells. In telomer-
ase positive cells TRF2 inactivation results in the 
immediate activation of the ATM/p53 axis for 
induction of cell death. In contrast, in ALT cells, 
where ATM is constitutively active, TRF2 in-
activation has two major effects: (1) Cellular 
senescence. (2) Loss of telomeric DNA. It is still 
unknown whether loss of telomeric DNA could 
itself trigger cellular senescence.JCB • VOLUME 179 • NUMBER 5 • 2007  864
deprotection, as end-to-end fusions can be induced in U2OS cells 
lacking TRF2 function (albeit in a small proportion of cells), 
thus indicating that the nonhomologous end joining (NHEJ) 
pathway is at least apparently functional. In contrast, long-term 
TRF2 inactivation or silencing results in p53 activation and 
induction of its target gene p21. This is accompanied by an ac-
cumulation in the G2 phase of cell cycle, reduced proliferation 
and induction of cellular senescence. Again, cell death is not a 
major component of the cellular response to TRF2 inactivation. 
These fi  ndings clearly indicate that the ALT cell line U2OS 
reacts differently to telomerase-positive tumor cells to alterations 
of the shelterin complex.
TRF2 is a component of the ALT-associated PML body 
(APB), a marker of ALT cells, which has been associated with 
telomere recombination and the ALT mechanism. Transient 
TRF2 silencing or ∆B∆M–dependent inactivation has no de-
tectable effects on localization of other APB components to this 
structure. This is in partial disagreement with a recent work, 
which showed that in the absence of TRF2 APBs are disrupted 
(Jiang et al., 2007). The reasons for this apparent discrepancy 
could be several. In particular, the abovementioned work used 
methionine restriction-induced cell cycle arrest to artifi  cially 
increase the number of APBs. In this respect, it is plausible that 
this treatment per se could have an impact on either APB forma-
tion or ALT. Furthermore, in the Jiang et al. work data were not 
confi  rmed using the ∆B∆M mutant. Interestingly, stable TRF2 
down-regulation or inactivation is associated with a decrease in 
the number of APBs, which is however concomitant to a de-
creased intensity and number of telomeric foci in the nucleus. 
Interestingly, we have demonstrated that TRF2-depleted U2OS 
and SUSM1 cells display a loss of telomeric DNA compared 
with control clones. It is presently unknown whether this is due 
to a decrease in chromosomal or extrachromosomal telomeric 
DNA. We cannot exclude the possibility that the ‘telomere pheno-
type’ of TRF2-depleted “survivor” clones could be somewhat 
selected as a pro-survival trait. Nonetheless, some lines of evi-
dence suggest that TRF2 is involved in controlling telomere 
erosion. For instance, it is known that in addition to inhibiting 
NHEJ, TRF2 can limit homologous recombination (HR)-induced 
T-loop deletions, which, if uncontrolled, has been shown to cause 
dramatic telomere attrition and induction of cellular senescence 
(Wang et al., 2004). T-loop deletions are increased in ALT cells, 
but this does not result in induction of cellular senescence (Wang 
et al., 2004). It could be hypothesized that in ALT cells TRF2 
could regulate the balance between T-loop deletions and telomere 
lengthening, which in turn could represent a checkpoint for in-
duction of senescence. As a result of this, the absence of TRF2 
would increase T-loop deletions, thus leading to irreversible 
growth arrest (Fig. 7 C). Alternatively, TRF2 could be involved 
in masking T-loop deletions to avoid further downstream signaling 
events. This is a fascinating hypothesis that needs to be tested in 
the near future.
A very recent paper has proposed that APBs represent 
sites for SUMOylation of TRF2 and other shelterin compo-
nents to allow for telomere recombination (Potts and Yu, 2007). 
Disruption of SUMOylation of the shelterin complex in ALT 
cells causes the induction of cellular senescence and telomere 
shortening, and this is accompanied by the disappearance of APBs. 
These data suggest a functional link between SUMOylation of 
shelterin components and telomere maintenance and/or protec-
tion from telomere erosion. More generally, they suggest that 
alterations of the shelterin complex in ALT cells result in telo-
mere attrition, which is what we see in our model system.
Recent studies have shown that concomitant TRF2 over-
expression and Tert inactivation in the mouse skin results in 
telomere attrition (Munoz et al., 2005; Blanco et al., 2007). This is 
apparently in confl  ict with our fi  ndings. However, in late gener-
ation TgTRF2/Tert
−/− animals ALT is activated and telomeres 
are elongated, suggesting that TRF2 allows ALT activation when 
telomeres are critically short or dysfunctional.
TRF2 functional inactivation results in uncapping of telo-
meres, which are recognized as damaged DNA (van Steensel 
et al., 1998; Karlseder et al., 1999, 2002). This triggers the acti-
vation of the ATM/p53 pathway for cell death induction in tumor 
cell lines and senescence in primary fi  broblasts (Karlseder et al., 
1999, 2002). Surprisingly, we found that ATM is constitutively 
phosphorylated in ALT cells and forms nuclear foci, some of 
which coincide with APBs. Despite the presence of active ATM, 
p53 is not activated and neither cell cycle arrest nor apoptosis is 
induced, thus suggesting that the effects of ATM on downstream 
DNA damage checkpoints are to a certain degree masked in 
ALT cells. Therefore, TRF2 would act either directly or in-
directly to inhibit the propagation of ATM-triggered signals. Another 
possibility is that ATM function in ALT cells is not limited to 
transducing a DNA damage signal. For instance, recent studies 
have demonstrated that ATM is required for correct telomere 
replication during S phase in primary fi  broblasts, thus revealing 
an unexpected role of ATM in telomere maintenance (Verdun 
et al., 2005; Verdun and Karlseder, 2006). We are currently in-
vestigating ATM function in ALT cells.
Finally, we have shown that p53 colocalizes with PML 
at APBs in a number of ALT cell lines but not in telomerase-
positive cells. Upon TRF2 silencing, PML is indispensable for 
p53-dependent p21 induction, while it does not affect p53 protein 
levels or its phosphorylation. It is therefore plausible that PML 
could affect other p53 posttranslational modifi  cations that govern 
its transcriptional activation. It is worth noting that p53 still 
accumulates at telomeres in PML-depleted cells. This suggests 
that p53 retains the ability to associate with dysfunctional telo-
meres in the absence of PML, but this is not suffi  cient to promote 
its activation.
In summary, our work indicates that differences exist be-
tween ALT cells and telomerase-positive cells in the way they 
react to disruption of TRF2 function and consequent telomere 
deprotection: (i) In telomerase-positive cells, TRF2 inhibition re-
sults in the activation of ATM and the induction of programmed 
cell death (Fig. 7 C). In contrast, in ALT cells ATM is constitu-
tively active, and TRF2 inactivation/silencing does not trigger 
apoptosis but rather causes the induction of cellular senes-
cence (Fig. 7 C). (ii) TRF2 depletion results in loss of telomeric 
DNA (Fig. 7 C), thus suggesting that it may affect the ALT 
mechanism. In this respect, the potential effect of HR-based 
T loop deletion on induction of cellular senescence should be 
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Materials and methods
Chemicals
All reagents used were from Sigma unless otherwise stated. Scrambled and 
TRF2 small interfering RNA oligonucleotides were purchased from Ambion.
Antibodies
Antibodies against PML (rabbit) and P-ATM were from Chemicon. Mouse 
anti–human PML (PGM3), mouse anti–human p53 (DO-1), goat anti–human 
PML (N19), rabbit anti-TRF2 (N-20) and rabbit anti-Bax were purchased 
from Santa Cruz Biotechnology. Antibodies against p21, phospho-ATM/ATR 
targets and phospho-serine 15 p53 were from Cell Signaling Technology 
(NEB). The anti-Phospho-Chk2 antibody was a kind gift of Dr. Tina Rich 
(Glasgow University) and was originally purchased from Upstate Bio-
technology. Antibodies against MRE11, TRF1 and phospho-NBS1 were pur-
chased from Abcam. Anti-Actin antibodies were purchased from Sigma-
Aldrich. Anti-γ-tubulin was a gift of Dr. Andrew Fry (University of Leicester). 
HRP-conjugated secondary antibodies were from Amersham Biosciences.
Cell culture
Human primary ﬁ  broblasts from newborn foreskin, designated BJ, were 
purchased from the American Type Culture Collection (ATCC). They were 
cultured in Dulbecco’s modiﬁ  ed Eagle’s medium (Invitrogen) supplemented 
with 20% fetal calf serum (Sera Laboratories International), SAOS-2 and 
U2OS osteosarcoma cell lines purchased from ATCC. These cell lines were 
maintained in Dulbecco’s Modiﬁ  ed Eagle’s Medium (DME) (GIBCO BRL) 
supplemented with 10% (vol/vol) heat inactivated fetal bovine serum (FBS). 
IIICF/A2 spontaneously immortalised cells were grown in RPMI 1640 
(GIBCO BRL) supplemented with 20% (vol/vol) heat inactivated FBS, 2mM 
glutamax (L-glutamine). JFCF6-T.1J/11E (ALT) and JFCF6-T.1J/11C (telomerase 
positive) were maintained in low glucose DME (GIBCO BRL) supplemented 
with 15% (vol/vol) heat inactivated FBS. The above three cells lines were 
a gift from Dr. Roger Reddel (Children’s Medical Research Institute, University 
of Sydney). SUSM-1 and GM847 SV40 were obtained from ATCC. The above 
mentioned cells were maintained in Modiﬁ  ed Eagle’s Medium (MEM) 
supplemented with 15% (vol/vol) heat inactivated FBS, 1% (vol/vol) Non-
Essential Amino Acids (NEAA) (GIBCO BRL). HeLa and MCF7 cell lines 
were obtained from ATCC and grown in DME (GIBCO BRL). Cells were 
grown in a humidiﬁ  ed incubator at 37C and 5% CO2/air. All media 
was supplemented with 100 U/ml penicillin (GIBCO BRL) and 100 mg/ml 
streptomycin (GIBCO BRL).
Small interfering RNA transient transfection
RNAi duplexes against PML and TRF2 mRNA were used. The oligo sequences 
are as follows: C  G  A  C  A  G  C  C  C  A  G  A  A  G  A  G  G  A  A  tt (PML sense); U  U  C  C  U  C-
U  U  C  U  G  G  G  C  U  G  U  C  G  tt (PML antisense); TRF2: G  A  G  G  A  U  G  A  A  C  U  G  U  U  U-
C  A  A  G  tt (TRF2 sense); C  U  U  G  A  A  A  C  A  G  U  U  C  A  U  C  C  U  C  tt (TRF2 antisense); 
G  G  A  G  G  A  G  U  U  C  C  A  G  U  U  U  C  U  G   (Exon2 sense); C  A  G  A  A  A  C  U  G  G  A  A  C  U  C-
C  U  C  C   (Exon2 antisense). The PML oligo was directed against exon 6 (nuclear 
localization signal), the Exon2 against exon2 and the TRF2 oligo as 
described by Xu and Blackburn (Xu and Blackburn, 2004). The oligos were 
transfected by electroporation using a Bio-Rad X-Cell electroporator. Eight mil-
lion cells were resuspended in 100 μl OptiMEM serum-free medium 
(Invitrogen) and transferred into 2 mm electroporation cuvettes (Molecular 
BioProducts). Cells were electroporated at 160 V using an exponentially 
decaying pulse. Cell viability was determined following electroporation using 
the trypan blue exclusion assay.
Stable transfection of shRNAs
U2OS cells were transfected with the pRetroSuper expression plasmid 
(oligoengine) containing the shRNAs against PML and TRF2 (as described 
above) using calcium phosphate. In brief, 18 μg of DNA (pSUPER.retro 
constructs) were dissolved in 125mM CaCl2 ﬁ  nal concentration. HBS (50 mM 
Hepes, pH 7.1, 300 mM NaCl, 1.5 mM Na2HPO4) solution was gently 
vortexed and the DNA-CaCl2 solution was added drop-wise. The solution 
was kept at room temperature for 30 min and then added drop wise to the 
cells seeded in a 10 cm dish and incubated 16 h at 37°C. The cells were 
extensively washed with PBS and then incubated in complete medium. 
Cells were selected with 1 μg/ml puromycin (Sigma-Aldrich). From pooled 
puromycin-resistant cells, individual colonies were isolated using 3-mm cloning 
discs (Sigma-Aldrich) folllowing the manufacturer’s instructions, and pas-
saged into medium containing 0.5 μg/ml puromycin. In bold are targeting 
sequences: P-all 5′-G  A  T  C  C  C  C  C  G  C  C  A  G  C  C  C  A  G  A  A  G  A  G  G  A  A  T  T  C  A  A  G  A-
G  A  T  T  C  C  T  C  T  T  C  T  G  G  G  C  T  G  G  C  G  T  T  T  T  T-3′ 3′-G  G  G  G  C  G  G  T  C  G  G  G  T  C  T  T  C  T-
C  C  T  T  A  A  G  T  T  C  T  C  T  A  A  G  G  A  G  A  A  G  A  C  C  C  G  A  C  C  G  C  A  A  A  A  A  T  T  C  G  A  -5′ TRF2 
5′-G  A  T  C  C  C  C  G  A  G  G  A  T  G  A  A  C  T  G  T  T  T  C  A  A  G  T  T  C  A  A  G  A  G  A  C  T  T  G  A  A  A  C  A  G-
T  T  C  A  T  C  C  T  C  T  T  T  T  T-  3′ 3′-G  G  G  C  T  C  C  T  A  C  T  T  G  A  C  A  A  A  G  T  T  C  A  A  G  T  T  C  T  C  T  G  A-
A  C  T  T  T  G  T  C  A  A  G  T  A  G  G  A  G  A  A  A  A  A  T  T  C  G  A  -5′
TET-On inducible TRF2
U2OS cells stably transfected with a TET-On plasmid were cultured in DME 
supplemented with 10% (vol/vol) heat inactivated TET-free FBS and 100 U/ml 
penicillin (GIBCO BRL) and 100 mg/ml streptomycin (GIBCO BRL). Cells were 
seeded in 150-mm dishes and transfected with the pSuperior expression 
plasmid (oligoengine) containing the shRNAs against TRF2 (as described 
above) using Effectene according to the manufacturers protocol (QIAGEN). 
In brief, 8 μg of DNA (pSuperior constructs), 1.2 ml Buffer EC, 32 μl 
Enhancer and 80 μl of Effectene were used. The cells were placed in selec-
tion 2 d after transfection in 1 μg/ml puromycin (Sigma-Aldrich). From 
pooled puromycin-resistant cells, individual colonies were isolated using 
3-mm cloning discs (Sigma-Aldrich) as per the manufacturer’s instructions, and 
passaged into medium containing 0.5 μg/ml puromycin: Cells were in-
duced with 0.5 mg/ml doxycycline and screened for positive clones by 
Western blotting.
TRF2
𝖫B𝖫M transient and stable transfection
U2OS cells were cotransfected with pBabePuro
R-NMycTRF2
∆B∆M (derived 
from pLPC-NMycTRF2
∆B∆M, a gift from Dr. Titia De Lange, Rockefeller 
University, NY) and 1/6 (molar ratio) of GFP using Effectene according 
to the manufacturers protocol (QIAGEN). Cells were sorted for GFP in 
a Becton Dickinson FACS Vantage. Recovered cells were cultured in com-
plete DME and 25 μg/ml Fungizone (Sigma-Aldrich) and collected at 
different time points after sorting for Western blotting, immunoﬂ  uorescence 
and metaphase spreads. U2OS cells were transfected with pBabePuro
R-
NMycTRF2
∆B∆M placed in selection 2 d after transfection in 1 μg/ml puromicin 
(Sigma-Aldrich). From pooled puromicin-resistant cells, individual colonies 
were isolated using 3-mm cloning discs (Sigma-Aldrich) as per the manu-
facturer’s instructions, and passaged into medium containing 0.8 μg/ml 
puromycin: Cells were screened for positive clones by Western blotting 
and immunoﬂ  uorescence.
Colony forming assay
Cells were seeded in 10-cm dishes and transfected as described above. 
Alternatively, inducible shTRF2 clones were plated at different densities 
and treated with doxycycline or left untreated. Colony formation was deter-
mined by crystal violet staining 10 d after selection. In brief, plates were 
placed on ice and washed twice with ice-cold 1× PBS. Cells were then 
ﬁ  xed with ice-cold methanol (stored at −20°C) for 10 min. Methanol was 
aspirated from the plates, and 0.5% crystal violet solution (made in 25% 
methanol and stored at room temperature) was added to cover bottom 
of plate and incubated at room temperature for 10 min. The crystal violet 
solution was poured off and the plates were carefully rinsed with distilled 
H2O until no color came off in the rinse. Plates were left to air dry at room 
temperature and colony numbers were determined using GeneSnap and 
GeneTools from Syngene.
Western blotting
Cells were lysed directly in SDS-sample buffer or in modiﬁ  ed RIPA lysis buffer 
containing 50 mM Tris pH 7.6, 150 mM sodium chloride, 0.5% Triton 
X-100, 2.5 mM sodium ﬂ  uoride, 2 mM sodium orthovanadate and a cocktail 
of protease inhibitors. Samples were analyzed by SDS-PAGE, transferred 
onto a nitrocellulose membrane and probed with the relevant antibodies.
Immunoﬂ  uorescence
Protein localization and expression were visualized by ﬂ  uorescence micros-
copy. For this purpose, cells were grown on glass coverslips and ﬁ  xed in 4% 
paraformaldehyde (PFA). After washing with PBS, cells were permeabilized 
using 0.1% Triton X-100 solution and blocked with 10% goat serum. Following 
incubation with the primary antibodies, cells were washed and incubated 
with ﬂ  uorescently labeled secondary antibodies (Molecular Probes). Image ac-
quisition and processing information: (1) Make and model of microscope: 
Zeiss Axiovert 200, Zeiss LSM510. (2) Type, magniﬁ  cation, and numerical 
aperture of the objective lenses: 40× plan neoﬂ  uor NA1.3; 63× plan apo-
chromat NA1.4. (3) Temperature: room temperature. (4) Imaging medium: 
Prolong Antifade kit (Invitrogen). (5) Fluorochromes; AlexaFluor 488, Alexa-
Fluor 555/568, AlexaFluor 647 (Invitrogen). (6) Camera make and model: 
Hamamatsu OrcaER. (7) Acquisition software: Zeiss Confocal software, 
Openlab Improvision Z-stacks were generated in 0.4-μm step increments, 
and 3D reconstructions were performed using software (Volocity; Improvision, 
Inc.). Images were processed using Adobe Photoshop 7.0. (8) Images were JCB • VOLUME 179 • NUMBER 5 • 2007  866
subsequently exported to TIFF. Figures were mounted using Adobe Photoshop 
and saved as JPEG ﬁ  les.
Hoechst staining
Cells were incubated with 2 μM Hoechst 33342, a cell-permeable nucleic 
acid stain, for 10 min and then analyzed by live microscopy. Snapshots of 
different ﬁ  elds were taken and mitoses (or apoptotic nuclei) analyzed.
PNA/FISH with IF
Cells were grown on coverslips and ﬁ  xed with ice-cold methanol-acetic acid. 
They were then prepared as for immunoﬂ  uorescence but were not mounted. 
After secondary antibody incubation, coverslips were washed in PBS 3 times 
for 5 min and post-ﬁ  xed in 4% PFA for 2 min. After three quick rinses in PBS 
the coverslips were dehydrated in EtOH in series 70%, 85%, 96% for 2 min 
each. Coverslips were then completely air dried. FITC- or rhodamine-
conjugated PNA probe (Panagene) stock was diluted 1:1,000 in hybrid-
ization solution (30% formamide, 0.1% Triton X-100, 0.3× SSC) and heated 
at 80°C for 3 min. Coverlips were then incubated in the dark at room temp 
for 30 min, rinsed in wash solution (4× SSC, 0.05% Tween 20) for 5 min. 
Cells were then counterstained with Dapi, mounted and stored at 4°C.
Apoptosis/cell cycle (PI staining)
To determine cell death PI staining and FACS analysis was performed. 
In brief, cells were ﬁ  xed in 70% EtOH, spun, washed in PBS and spun again. 
The pellet was resuspended in 60 μl of PBS with 300 μg/ml RNase and 
incubated for 30 min at room temperature. 10 μg/ml of propidium iodide 
was then added and samples were incubated in the dark for 30 min before 
being analyzed through a Becton Dickinson FACS machine. DNA proﬁ  les 
were analyzed using the CellQuest acquisition/analysis software.
Cell size
Live cells were run through a Schaerfe System (Casy) machine and cell 
diameter was determined. Alternatively, cells were ﬁ  xed with 70% EtOH and 
run through a BD FACS. Forward scatter (FSC-H) histograms of different 
clones were compared.
Senescence
Cells were ﬁ  xed in 4% PFA and stained with the SA-βGal solution (5 mM 
potassium ferrocyanide, 5 mM potassium ferricyanide, 40 mM citric acid, 
166 mM Na2HPO4, 40 mM NaH2PO4, 2 mM MgCl2, 375 mM NaCl, 
1 mg/ml X-Gal, pH 6.0) for 6–24 h. Cells were then analyzed by 
light microscopy.
Immunoprecipitation
Samples were collected and lysed in ice cold lysis buffer (50 mM Tris, pH 7.6, 
150 mM sodium chloride, 0.5% Triton X-100, 2.5 mM sodium ﬂ  uoride, 
and 2 mM sodium orthovanadate) with protease inhibitors. 500–1,000 μg 
of total protein, as determined by Bradford assays, was precleared and 
then incubated with 500 ng of Protein G agarose-conjugated antibody at 
4°C for 3 h, followed by 1-h incubation with Sepharose beads. After ﬁ  ve 
washes with ice-cold lysis buffer containing protease and phosphatase in-
hibitors, the immunoprecipitates were subjected to Western analysis as 
described above.
FlowFISH analysis
FlowFISH was performed following the protocol by Lansdrop and colleagues 
(Rufer et al., 1998).
Cytogenetic analysis
Cells were harvested for cytogenetic analysis using standard techniques. 
In brief, cells were arrested at metaphase with colcemid (ﬁ  nal concentration 
0.05 μg/ml 1–2 h). After detachment cells were treated with a hypotonic 
solution of KCl (0.075 M), ﬁ  xed using 3:1 methanol/glacial acetic acid and 
slides prepared. Telomeres were detected using ﬂ  uorescent in situ hybrid-
ization (FISH) to a to Rhodamine conjugated peptide nucleic acid (PNA) 
probe (Rho-OO-C  C  C  T  A  A  C  C  C  T  A  A  C  C  C  T  A  A  , PE Biosystems) or a similar PNA 
conjugated to FITC. PNA hybridization was conducted as described pre-
viously (Lansdorp et al., 1996; Zijlmans et al., 1997) and cells were counter-
stained with DAPI. Digital images were captured with the Smartcapture 
software (Digital Scientiﬁ  c) using a 63 or 100× objectives on a Zeiss Axioskop 
microscope ﬁ  tted with a multiple ﬁ  lter wheel and suitable ﬁ  lters.
Genomic DNA extraction and Southern blot procedure
Genomic DNA was extracted from stable clones at various passages. In brief, 
10
7 cells were trypsinized, washed and resuspended in 500 μl 1× SSC. 
Subsequently, 500 μl of 2× lysis buffer (100 mM Tris HCl, pH 7.5, 100 mM 
NaCl, 10 mM EDTA, and 1% Sarkosyl) were added together with 50 μg/ml 
of RNase, and the samples were left to stand at room temperature for 20 min 
before adding 500μg/ml of proteinase K and leaving them rotating over-
night at 55°C. The samples were then subjected to phenol/chloroform 
extraction and subsequent ethanol precipitation. DNA concentration was 
measured using a spectrophotometer. Approximately 5μg of puriﬁ  ed genomic 
DNA was digested with the restriction enzymes Hinﬂ   and RsaI (NEB). The di-
gested DNA was quantiﬁ  ed and 3.0 μg was loaded on a 1% agarose 
gel in 0.5× TBE. Samples were electrophoresed in a CHEF-DR III pulse-ﬁ  eld 
electrophoresis apparatus (Bio-Rad Laboratories) in recirculating 0.5× TBE 
buffer at 14°C. Electrophoresis conditions were 5v per cm for 12 h with a 
0.5–1.5 switch time. The gel was rinsed and stained with ethidium bro-
mide to visualize the DNA and a Southern blot produced on Hybond N+ 
membrane using standard techniques. Southern blot membrane was hybrid-
ized to a 
32P-αdCTP labeled telomere probe in modiﬁ  ed Church buffer (EDTA 
1 mM, NaHPO4, pH 7.2, 0.5 M SDS 7%) at 65°C and subsequently 
washed in 1.0×SSC, 0.1% SDS at 65°C. The blot was visualized using a 
PhosphorImager (Typhoon; GE Healthcare) and telomere length determined 
using the Telometric Software (Fox Chase Cancer Center, Philadelphia, PA). 
Subsequently the blots were hybridized to a 
32PαdCTP labeled MS1 mini-
satellite probe (Jeffreys et al., 1988) as loading control between tracks.
Online supplemental material
Figure S1 shows the effects of TRF2 RNAi or functional inhibition on cell 
viability and end-to-end fusions. Figure S2 shows the effect of TRF2 RNAi 
or functional inhibition on genomic stability and cell size. Figure S3 shows 
the effect of TRF2 RNAi on APBs. Figure S4 contains loading controls for 
TRF (A and B) and FlowFISH (C). Figure S5 shows ATM and ATM targets 
localization with respect to APBs in various ALT and telomerase-positive 
cell lines (A–D). Moreover, the ﬁ  gure contains an analysis of p53 ex-
pression and localization pattern in ALT and telomerase positive cells (E–I). 
Online supplemental material is available at http://www.jcb.org/cgi
.content/full/jcb.200703020/DC1.
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